摘要目的 探讨经尿道膀胱肿瘤切除术(TURBT)结合表柔比星对浅表性膀胱癌患者生存预后的影响.方法 选取2011年6月至2014年6月在本院行TURBT术的浅表性膀胱癌患者100例,依据随机分配原则分为霉素组和比星组,各50例.霉素组术后给予40 mg丝裂霉素治疗,比星组术后给予30 mg表柔比星治疗.结果 霉素组和比星组治疗后3、6个月血清血管内皮生长因子(VEGF)水平低于治疗前,比星组治疗后3、6个月VEGF水平明显高于霉素组,差异有统计学意义(P＜0.05).霉素组和比星组不良反应发生率基本相同,差异无统计学意义(P＞0.05).比星组在第1、2、3年累积生存率明显高于霉素组,比星组在第1、2、3年累积复发率明显低于霉素组,差异有统计学意义(P＜0.05).结论 TURBT术结合表柔比星可有效减少浅表性膀胱癌患者术后复发和改善生存预后,其可能与降低患者血清VEGF水平有关,且具有良好的安全性,值得临床推广.

abstractsObjective To investigate the effect of transurethral resection of bladder tumor (TURBT) combined with epirubicin for the serum vascular endothelial growth factor (VEGF) level and survival prognosis in patients with superficial bladder cancer.Methods From June 2011 to June 2016,100 patients with superficial bladder cancer were selected in our hospital.All patients were randomly divided into mitomycin group and epirubicin group,50 cases in each group,mitomycin group was treated with 40 mg mitomycin after the operation,epirubicin group was treated with 50 mg epirubicin after the operation.Results VEGF levels of mitomycin group and epirubicin group at 3,6 months after treatment were significantly lower than those of the before treatment,VEGF levels of epirubicin group were significantly lower than those of mitomycin group at 3,6 months after treatment,the difference was statistically significant (P ＜ 0.05),the adverse reaction rates of mitomycin group and epirubicin group were basically the same,there was no statistically significant difference (P ＞ 0.05).Cumulative survival rate of epirubicin group was significantly higher than those of mitomycin group,and cumulative recurrence rate of epirubicin group was significantly lower than those of mitomycin group at 1 year,2 years,3 years,and the difference was statistically significant (P ＜ 0.05).Conclusions TURBT combined epirubicin can effectively reduce postoperative recurrence and improve survival prognosis in patients with bladder cancer,it may be associated with reducing the serum VEGF level in patients,and it has a good safety,it's worth for further clinical promotion.